New Brunswick Family Medicine · 200 patients
Good evening, Dr. Rivera.
5 trials fit your patients, with 188 pre-screen candidates between them. Ranked by how many of your patients could join. We pre-screened your panel against 39 open trials on Oct 11, 2026; patient records never left your practice.
Overweight or Obesity
REGN20934
This study will test a study drug called REGN20934 to see how safe and well tolerated this drug is, as well as how the drug is processed in the body for participants with overweight or obesity. The study is looking at: * What side effects REGN20934 might cause * How much REGN20934 is in the blood at different times *…
- Ages
- 18–65
- Sex
- All
- Enrolling
- 90
- Ends
- Feb 2027
Overweight or Obesity
Olatorepatide
This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing side effects, as well as how the drug is processed in the body by…
- Ages
- 18+
- Sex
- All
- Enrolling
- 360
- Ends
- Jan 2028
Hypercholesterolemia
Alirocumab
This study is researching an experimental drug called alirocumab, referred to as "study drug". In the United States, alirocumab is approved for the treatment of hypercholesterolemia (high blood cholesterol levels). The aim of the study is to see how safe and effective alirocumab is when given weekly to adult…
- Ages
- 18–80
- Sex
- All
- Enrolling
- 420
- Ends
- Dec 2026
Diabetic Kidney Disease
Evinacumab
This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on participants who have diabetic kidney disease. The aim of the study is to see how safe and effective the study drugs are. The study is looking at several other research questions, including: * What side…
- Ages
- 18–80
- Sex
- All
- Enrolling
- 195
- Ends
- Oct 2028
Familial Hypercholesterolemia
Supportive care
Hypercholesterolemia is recognized as the major driver for cardiovascular morbidity and mortality. To help address this in our community, Atlantic Medical Group (AMG) formed a lipid workgroup chaired by Robert D. Fishberg, MD, and Jeffrey N. Feldman, MD. The overarching goal of the lipid workgroup is to enhance the…
- Ages
- 18–120
- Sex
- All
- Enrolling
- 250
- Ends
- May 2027
No candidates in your panel· 10
Open trials where none of your patients pre-screened as a candidate or for chart review, or that haven't been pre-screened yet.
Metabolic Dysfunction-Associated Steatotic Liver Disease
Tirzepatide
This study will test a study drug called ALN-PNP with and without another drug that is used for controlling blood sugar, appetite, and weight (for example, tirzepatide), to see if it can help treat MASLD, also known as fatty liver disease. ALN-PNP reduces the amount of Patatin-like phospholipase domain-containing…
- Ages
- 18–75
- Sex
- All
- Enrolling
- 204
- Ends
- Mar 2030
Metabolic Dysfunction-Associated SteatoHepatitis
ALN-HSD
This study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have Metabolic dysfunction-Associated SteatoHepatitis (MASH). MASH is a form of Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD). MASH occurs when fat builds up in…
- Ages
- 18–75
- Sex
- All
- Enrolling
- 120
- Ends
- Apr 2028
Monogenic Obesity
Mibavademab
This study is researching an experimental drug called mibavademab. The study is focused on patients with a condition called monogenic obesity. Monogenic obesity is caused by a change in the leptin gene that keeps it from working properly. This causes the body to not be able to feel full or control feelings of hunger.…
- Ages
- 2+
- Sex
- All
- Enrolling
- 4
- Ends
- Jun 2027
Metabolic Dysfunction-Associated Steatotic Liver Disease
ALN-CIDEB
This study is researching an experimental drug called ALN-CIDEB, also referred to as "study drug". The study is focused on participants with metabolic dysfunction-associated steatotic liver disease (MASLD) (Part A) and metabolic dysfunction-associated steatohepatitis (MASH) (Part B). MASLD and MASH are long-lasting…
- Ages
- 18–65
- Sex
- All
- Enrolling
- 132
- Ends
- May 2027
Healthy Volunteers
ALN-PNP
This study is researching an experimental drug called ALN-PNP (called "study drug"). This is a first in human study. The study drug is not approved by any public health agency such as the United States Food and Drug Administration (FDA) for any kind of treatment. This study consists of 3 parts. Part A is focused on…
- Ages
- 18–75
- Sex
- All
- Enrolling
- 172
- Ends
- Aug 2027
Hemodialysis
Alirocumab 150 MG/ML [Praluent]
12-week study of the efficacy and safety of alirocumab in patients maintained stably on hemodialysis or peritoneal dialysis. Measures of cholesterol levels, drug levels, PCSK9 levels, routine chemistry and cell counts, and biomarkers will be obtained at baseline and at weeks 4, 8, 10 and 12 weeks. Safety events will…
- Ages
- 18–80
- Sex
- All
- Enrolling
- 20
- Ends
- Aug 2020
Generalized Lipodystrophy
Mibavademab
This study is researching a new drug called mibavademab (called "study drug"). The study involves participants with a condition called Generalized Lipodystrophy (GLD). The aim of the study is to see how well mibavademab works and what side effects it has. Researchers will also look at how much mibavademab is in the…
- Ages
- 2+
- Sex
- All
- Enrolling
- 28
- Ends
- May 2028
End-Stage Kidney Disease
REGN9933
This study will evaluate three Investigational Medicinal Products (IMPs) called REGN9933, REGN7508, and REGN9533. The study is focused on participants with End-Stage Kidney Disease (ESKD) treated with hemodialysis and standard anticoagulant treatment, such as heparin, to reduce the risk of blood clots as they can lead…
- Ages
- 18+
- Sex
- All
- Enrolling
- 36
- Ends
- Apr 2027
Metabolic Dysfunction-Associated Steatohepatitis
ALN-CIDEB
This study will test a Regeneron study drug called ALN-CIDEB to find out whether it may help treat a liver disease called MASH. In this study, researchers are looking at the effect of ALN-CIDEB on reducing liver fat, liver injury, and liver scarring. The study will compare ALN-CIDEB with placebo to understand how well…
- Ages
- 18–75
- Sex
- All
- Enrolling
- 150
- Ends
- Feb 2029
Metabolic Dysfunction-Associated Steatotic Liver Disease
ALN-CIDEB
This study will test a Regeneron study drug called ALN-CIDEB to find out whether it may help treat a liver disease called metabolic dysfunction-associated steatohepatitis (MASH). MASH is more advanced stage of a broader liver disease, MASLD. MASLD is a liver condition caused by too much fat building up in the liver.…
- Ages
- 18–75
- Sex
- All
- Enrolling
- 1,500
- Ends
- Mar 2029